Claudia Maletzki

27PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)BiofabricationSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 30, 2026
Hsa-miR-25-3p Inhibition Sensitizes Patient-Derived Glioblastoma Cells to Temozolomide via β-catenin Downregulation.

|Aug 02, 2025
CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid-a promising combination strategy for therapeutic intervention.

Fatemeh Shokraie, Larissa Lechermeier, Pia Bordihn

|Apr 26, 2025
Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat.

Stefan Senekowitsch, Thomas Freitag, Daniel Dubinski

|Oct 26, 2024
Correction: Becker et al. Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response. Cancers 2023, 15, 5597.

Anne-Sophie Becker, Cornelius Kluge, Carsten Schofeld

|Jul 25, 2024
Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma.

Thomas Freitag, Philipp Kaps, Justus Ramtke

|Mar 28, 2024
Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.

Said Kdimati, Clemens Christoph, Änne Glass

Pageof 5

Frequent Collaborators

8 joint publications

Björn Schneider

4 joint publications

Daniel Strüder

3 joint publications

Thomas M Freiman

3 joint publications

Heiko Lemcke